UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* CAPPELLO ALEXANDER L			2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director Officer (give title below) Other (specify below)				
(Last) (First) (Middle) 4995 BRADENTON AVE., SUITE 240			3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022									
DUBLIN, OH 43017			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
e)	(Zip)	Т-	LL I N.	D			A	d D:) e . : . II	01	
2. Transaction Date		2A. Deemed Execution Date, if any	3. Transaction Code (Instr. 8)				uired of	d 5. Amount of Securities		es ollowing	6. Ownership Form: Direct (D)	Beneficial Ownership
			Code	V	Amoun	(A) or (D)	Price				or Indirect (Instr. 4) (I) (Instr. 4)	
01/3	31/2022		A		2,500 (1)	A	\$ 0	43,977			D	
									OMB con	trol numbe	r.	
rsion Date Excreise (Month/Day/Year) Ex	3A. Deemed Execution Date, if											
	Execution Date any	e, if Transaction Code (Instr. 8)	5.	6. Da and E (Mon		tible secur cisable on Date	7. Ti Amo Undo	tle and ount of erlying trities r. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	Owners Form of Derivati Security Direct (or Indire	Benefic Owners (Instr. 4
et et	DER L (i) (i) (iii) (iv) (iv) (iv) (iv) (iv)	DER L (Middle) (/E., SUITE 240 e) (Zip) 2. Transaction Date (Month/Day/Year) 01/31/2022 e line for each class of securi	DER L NAVIDEA BIO [NAVB] 3. Date of Earliest 01/31/2022 4. If Amendment, (Zip) Ta 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 01/31/2022 te line for each class of securities beneficially over	DER L NAVIDEA BIOPHARI [NAVB] 3. Date of Earliest Transaction 01/31/2022 4. If Amendment, Date Origin 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Code (Instr. 8) Code 01/31/2022 A Te line for each class of securities beneficially owned direct	DER L NAVIDEA BIOPHARMAC [NAVB] 3. Date of Earliest Transaction (Mo 01/31/2022 4. If Amendment, Date Original File (Zip) Table I - Non-Derivation Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 24. Deemed Execution Date, if any (Month/Day/Year) Code (Instr. 8) Code V 101/31/2022 A Persecontation of the feed of t	NAVIDEA BIOPHARMACEUTION [NAVB] 3. Date of Earliest Transaction (Month/Day/TE., SUITE 240 4. If Amendment, Date Original Filed(Month) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Execution Date, if any (Month/Day/Year) 2. Transaction Code (Instr. 8) (Instr. 8) Code V Amour Code V Amour Persons where the form distributed in	NAVIDEA BIOPHARMACEUTICALS, II [NAVB] 3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022 4. If Amendment, Date Original Filed(Month/Day/Year) 2. Transaction Date (Month/Day/Year) 4. Securities Acquired (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 4. Securities Acquired (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Persons who resport ontained in this for the form displays a description of the form display and description of the form display and description of the form display and	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] 3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022 4. If Amendment, Date Original Filed(Month/Day/Year) 2. Transaction Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed of (Instr. 8) (ID) (Instr. 3, 4 and 5) Code V Amount (A) or (D) Price 2.500 A 9 Persons who respond to the contained in this form are the form displays a current	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] 3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual X_Form file Form file	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] X_Director Officer (give title below) X_Director Officer (give the Acquired of O	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] 10% (Owner Officer (give title below) 10% (Owner Specify below)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
CAPPELLO ALEXANDER L 4995 BRADENTON AVE., SUITE 240 DUBLIN, OH 43017	X					

Signatures

/s/ Erika L. Eves for Alexander L. Cappello, by power of attorney	02/01/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.